A Study of Single-dose ALXN2050 in Healthy Adults

Key Inclusion Criteria: * Healthy was defined as having no clinically relevant abnormalities identified by a detailed medical history, physical examination, blood pressure and heart rate measurements, 12-lead ECG, and clinical laboratory tests. * Had a body mass index of 18 to 30 kilograms (kg)/meter squared with a minimum body weight of 50 kg. * Female participant of nonchildbearing potential. * Male participant agreed to abstinence or use of a highly effective form of contraception. Key Exclusion Criteria: * Had a history or clinically relevant evidence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. * Had any condition possibly affecting drug absorption. * Had a body temperature greater than or equal to 38°Celsius on Day -1 or Day 1, Hour 0; had a history of febrile illness, or other evidence of infection, within 14 days prior to first study drug administration. * Had a positive urine drug screen at Screening or Day -1; was a current tobacco/nicotine user or smoker; had consumed any alcohol within 72 hours before first study drug administration or had a history of regular alcohol consumption within 6 months of Screening. * Had participated in a clinical study within 30 days prior to first study drug administration * Had clinically significant laboratory abnormalities, * Had donated blood or lost more than 500 milliliters of blood within 3 months prior to first study drug administration; had received a blood transfusion or blood products within 6 months prior to first study drug administration. * Had a clinically significant history of drug allergy.